Fig. 2: Survival analysis in resectable PDAC patients with or without plasma KRAS and KRAS G12D mutation in the discovery cohort. | British Journal of Cancer

Fig. 2: Survival analysis in resectable PDAC patients with or without plasma KRAS and KRAS G12D mutation in the discovery cohort.

From: Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients

Fig. 2

a OS for resectable PDAC patients with (n = 26, red) and without (n = 87, blue) KRAS mutants in ctDNA. In total, 73.1% of patients with KRAS mutations survived at 12 months post surgery vs 82.8% for the patients without KRAS mutations. b RFS for resectable PDAC patients with (n = 26, red) and without (n = 87, blue) KRAS mutations in ctDNA. In all, 42.3% of patients with KRAS mutations were recurrence-free at 12 months post surgery vs 65.5% for the patients without KRAS mutations. c OS for resectable PDAC patients with (n = 13, red) and without (n = 100, blue) KRAS G12D mutant in ctDNA. d RFS for resectable PDAC patients with (n = 13, red) and without (n = 100, blue) KRAS G12D mutation in ctDNA. e Comparison for recurrence types of resectable PDAC patients with (n = 13) and without (n = 100) KRAS G12D mutation in ctDNA.

Back to article page